Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relative Bioavailability of Two Survodutide (BI 456906) Formulations When Administered Subcutaneously Via Pre-filled Syringe Over 28 Weeks (an Open-label, Randomised, Multiple Dose, Parallel Group Trial)

NCT07221591 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07221591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07221591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relative Bioavailability of Two Survodutide (BI 456906) Formulations When Administered Subcutaneously Via Pre-filled Syringe Over 28 Weeks (an Open-label, Randomised, Multiple Dose, Parallel Group Trial)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
November 5, 2025
Completion date
July 28, 2026
Enrollment
100 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy